HCP RESOURCES

Multitarget Stool DNA Tests Increase Colon Cancer Screenings

World Journal of Gastroenterology | Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients second image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients third image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients forth image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients fifth image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients sixth image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients seventh image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients eighth image.
Multitarget stool DNA test increases colorectal cancer screening among previously noncompliant Medicare patients ninth image.

Important Information about the Cologuard products 


Indications for Use 

The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.


Contraindications 

The Cologuard products are not for high-risk individuals, including patients who have the following:  

  • a personal history of colorectal cancer and adenomas 
  • a positive result from another colorectal cancer screening method within a test recommended timeframe 
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease 
  • have a family history of colorectal cancer, or certain hereditary syndromes 

Warnings and Precautions 

All positive results should be referred to colonoscopy.


The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC. 


A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established. 


Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.


Rx only.